Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients [Seeking Alpha]
Cerus Corporation (CERS)
Last cerus corporation earnings: 2/20 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cerus.com/investors/investor-overview/default.aspx
Company Research
Source: Seeking Alpha
The trial demonstrated non-inferiority of the incidence of acute kidney injury for INTERCEPT Red Blood Cells compared to conventional red blood cells The safety endpoint of the proportion of patients with any related treatment-emergent adverse events within 28 days of last transfusion was not significantly different for INTERCEPT RBCs (2.5%) compared to conventional RBCs (0.6%) (p = 0.130). There was no clinical significance related to treatment-emergent RBC antibodies observed in five patients receiving INTERCEPT RBCs. Cerus anticipates initiating a modular PMA application to the FDA in the second half of 2025, with the final PMA module submission planned for the second half of 2026, upon the anticipated completion of the RedeS clinical trial. Recommended For You More Trending News Recommended For You More Trending News About CERS Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
CERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERS alerts
High impacting Cerus Corporation news events
Weekly update
A roundup of the hottest topics
CERS
News
- Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024Business Wire
- Cerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64% [Yahoo! Finance]Yahoo! Finance
- Cerus gains as Craig Hallum launches at Buy on return to growth [Seeking Alpha]Seeking Alpha
- Cerus Co. (NASDAQ: CERS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life [Yahoo! Finance]Yahoo! Finance
CERS
Earnings
- 3/5/24 - In-Line
CERS
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 4/26/24 - Form ARS
- CERS's page on the SEC website